An improved process for the synthesis of all (e)-hepta prenol (c35-oh)

The synthesis of all-trans heptaprenol is enhanced by a novel process that simplifies the reaction steps and maintains stereoselectivity, resulting in higher yields and economic benefits.

WO2025074315A2PCT designated stage expired Publication Date: 2025-04-10SYNERGIA LIFE SCIENCES PVT LTD
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
PCT/IB2024/059716
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2024-02-13
Filing Date
2024-10-04
Publication Date
2025-04-10

AI Technical Summary

Technical Problem

Current methods for synthesizing all-trans heptaprenol are inefficient due to the need for multiple reaction steps and the loss of stereoselectivity, leading to low yields and high recovery costs.

Method used

A novel synthesis process that incorporates a second phenyl sulphonyl group into the molecule, allowing for a single-step reduction to remove both phenyl sulphonyl groups, thereby reducing the number of reaction steps and eliminating the need for intermediate purification.

Benefits of technology

This improved process results in higher product yields, improved process economy, and maintains stereoselectivity, addressing the inefficiencies and cost issues of existing methods.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure IMGF000005_0001
    Figure IMGF000005_0001
  • Figure IMGF000006_0001
    Figure IMGF000006_0001
  • Figure IMGF000006_0002
    Figure IMGF000006_0002
Patent Text Reader

Abstract

The present disclosure relates to an improved process for the regio- and stereospecific synthesis of polyprenyl compounds. More particularly it discloses regio- and stereospecific synthesis of (2E,6E,10E,14E,18E,22E)-3,7,11,15,19,23,27-heptamethyloctacosa-2,6,10,14, 18, 22,26 heptane-1-ol which finds use in the synthesis of Vitamin K2-7.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] AN IMPROVED PROCESS FOR THE SYNTHESIS OF ALL (E)-HEPTA PRENOL (C35-OH)

[0002] RELATED APPLICATION

[0003] This application is related to and takes priority from Complete Application 202321066937 filed 5thOctober 2023 and Complete Application 202421009595 filed 13thFebruary 2024, both of which incorporated herein in its entirety.

[0004] FIELD OF INVENTION

[0005] The present disclosure relates to an improved process for the regio- and stereospecific synthesis of polyprenyl compounds. More particularly it discloses regio- and stereospecific synthesi s of (2E,6E, 10E, 14E, 18E,22E)-3 ,7,11,15,19,23,27 -heptamethyloctacosa-2, 6, 10,14, 18, 22,26 heptane-l-ol which finds use in the synthesis of Vitamin K2-7.

[0006] BACKGROUND OF THE INVENTION

[0007] Polyprenols denote a family of unsaturated, acyclic, aliphatic alcohols bearing at least four isoprene units linked head-to-tail wherein the hydroxyl group is attached to the head of the chain. The members differ from each other in their chain length and the stereochemistry of their internal isoprene units. Polyprenols are integral components of biological membranes of living cells, and are present either as free alcohols and / or their carboxylic esters. Three types of natural polyprenols are (a) all-trams-polyprenols, (b) ditrans polycis- or tritrans , polycis- prenols, and (c) ditrans, polycis a - saturated prenols. Polyprenols are widely are found in bacteria, plants, yeast and fungi. Umbreit et. al. (J. Bacteriology (1972), 1302-1305) isolated and characterized C5-isoprenyl alcohol and its derivatives from Streptococcus faecalis. Basyuni et. al. (Sys Rev Pharm (2020) 11(7): 89-97) analysed the distribution of polyprenyl alcohols in the seed tissues of oil palms using two-dimensional thin layer chromatography. Polyprenols are reportedly non-toxic, non-mutagenic, non-teratogenic and non-carcinogenic in humans. They exhibit anti-tumour, anti-hepatitis C virus and anti-HIV effects and are used as adjuvants for chemotherapy for leukaemia and radiotherapy. They are also remedy for hypertension, high cholesterol, diabetes, gout, lupus and other immune function disorders and have therefore been widely researched. Substitution of the hydroxyl group has been explored for applications in the development of anti-tumour and anti-anaemia effects, and as antipsychotic drugs. Prenylacetic esters exhibit anti-ulcer and antithrombotic activities. EP 0 239 729 B l discloses polyprenyl alcohol-containing injections for enhancing utilization of polyprenyl alcohol in vivo. Larodan in Sweden and Indofine in the US, supply polyprenols. The medicinal product Ropren which exhibits cerebroprotective and hepatoprotective effects, contains a 95% purity concentrate of polyprenols. (Zhang et. al. Fitoterapia 106 (2015) 184- 193).

[0008] Solanesol was the first polyprenol to be isolated from tobacco leaves with methanol and ether. It has also been isolated from tobacco, mulberry and from unsaponifiable matter of silkworm faeces. Polyprenols were isolated from a contaminant of cellulose pulp in a paper plant. The isolation, purification, synthesis, structure and function biological activity correlation, and pharmacology of polyprenols and derivatives has been extensively studied and reviewed. Yan et.al. (Phytochem. Rev. (2015)14 (3) 403-417) reviewed resources, derivatives, bioactivities, medicinal applications, and biosynthesis of Solanesol.

[0009] While polyprenols are widely distributed in nature, their low content in plants and low yields during isolation and purification leads to high recovery costs.

[0010] Muramatsu et. al. (J.Biosci. and Bioengg.106 (3) 263-267 (2008), J. Biosci. and Bioengg. (108) (1) 52-55, (2009)) described microbial production farnesol and related prenyl alcohols In view of their diverse applications and importance in the synthesis of isoprenoid quinones of biological importance and limited occurrence in nature, efforts have been made for the synthesis of polyprenols especially all trans polyprenols.

[0011] Cheng and Loh (Pure Appl. Chem., 77, (7)1199-1206, 2005.) disclosed asymmetric a- prenylation of various aldehydes to yield corresponding a-prenyl alcohols.

[0012] Sato et al (J Chem Soc Perkin I (1981) 761) reported stereo selective synthesis of solanesol and all-trans- decaprenol. Altman et al (J . Am.Chem. Soc., 1972, 94, 3257; Synthesis, 1974, 129) reported the synthesis of all trams-geranyl geraniol.

[0013] Masaki et. al. (Tetrahedron Lett. (1978), 4539, J. Chern. Soc., Chern. Comm., (1979), 855; Tetrahedron Lett., 1978, 5123) discussed the preparation of terminal trans-allylic alcohols from linear isoprenoids.

[0014] Turi and Crans (Molecules (2020), 25, 4477-4514) in a review of synthesis of naphthoquinone derivatives disclosed the Diels-Alder reactions between the naphthoquinone and polyprenyl halides for the synthesis of vitamin K.

[0015] Synthesis of polyprenyl acetate was reported by Zhou et al. (Chem. Ind. For. Prod. 33 (2013) 53-56).

[0016] The synthesis of long chain poly isoprenyl alcohols entails coupling two all-trans polyprenyl side chains. Although explored by researchers (WO 2011 / 117324 A2 and WO 2010 / 034999 Al), Biellmann chemistry doesn’t always ensure the retention of all-trans character. Synthesis of polyprenyl alcohols starting from farnesol adding one prenyl unit at a time, retaining the stereoselectively was described by Coates et. al (Org. Synth. 2007, 84, 43-57). However, it has been recognized that as the number of prenyl units increases, it may not be practical to add one unit at a time since overall yield of the process decreases at each step.

[0017] US 9,012,693 disclosed that Biellmann chemistry could be exploited to make polyprenyl compounds. It disclosed a method to synthesize heptaprenol from farnesol.

[0018] US patent 9,464,021 B2 (2016) pointed out the loss of stereoselectivity when Biellmann chemistry was used to synthesize higher polyprenols and disclosed polyprenyl side chain bearing 1,3-dithiane terminal group for the synthesis of Vitamin K2.

[0019] The patent application 20232100851, “Synthesis of polyprenyl alcohols” disclosed that starting from commercially available building blocks such as isoprene, farnesol, farnesol acetone, geraniol, polyprenyl (phenyl sulfonyl) alcohols bearing 5 to 10 prenyl units can be obtained which can then be desulphonated in the presence of a catalyst, a reducing agent and a mixture of solvent and a co-solvent to yield polyprenyl alcohols.

[0020] The synthesis of (2E,6E,10E,14E,18E,22E)-3,7,l l,15,19,23,27-heptamethyloctacosa-2,6, 10,14,18,22,26 heptaen-l-ol according to the method of the patent application 20232100851 involved incorporation of phenyl sulphonyl group and its removal by reduction in the presence of super hydride followed by incorporation of a second phenyl sulphonyl group, reaction with chloro isoprenyl acetate followed by hydrolysis and removal of the second phenyl sulphonyl group by a second reduction in the presence of the super hydride.

[0021] SUMMARY OF THE INVENTION

[0022] It has now been surprisingly found that (2E,6E,10E,14E,18E,22E)-3,7,l l,15,19,23,27-hepta methyloctacosa-2,6, 10,14,18,22,26 heptaen-l-ol can be synthesized by incorporating the second phenyl sulphonyl group into l-((2E,6E,10E,14E,18E)-l-chloro-3, 7, 11,15,19,23- hexamethyl tetracosa-2,6,10,14,18,22-hexaen-9-ylsulfonyl)benzene by reacting with sodium benzene sulphinate, in DMF , reacting l-((2E,6E,10E,14E,18E)-3,7,l l,15,19,23-hexamethyl -1 -(phenylsulfonyl) tetracosa-2,6,10,14,18,22-hexaen-9-ylsulfonyl) benzene obtained with 4- chloro prenyl acetate followed by hydrolysis and removal of both phenyl sulphonyl groups by reduction in a single step in the presence of super hydride.

[0023] (2E,6E,10E,14E,18E,22E)-3,7,ll,15,19,23,27- heptamethyloctacosa-2,6, 10,14,18 ,22,26-heptaen- 1 -ol M.W = 494.83 M.F = C35H58O

[0024] The improved synthesis method has the advantage that it eliminates one reaction step of reduction in the presence of super hydride before the introduction of the second phenyl sulphonyl group, and the need for the purification of the compound of the intermediate step. The improved process has the advantage of 1) reducing the number of reaction steps, 2) eliminating the need for the purification of the reaction intermediate 3) higher product yield and improved process economy.

[0025] In an embodiment of the disclosure l-((2E,6E,10E,14E,18E)-l-chloro-3,7,l l,15,19,23- hexamethyltetracosa -2,6,10,14,18,22-hexaen-9-ylsulfonyl)benzene is reacted with Sodium benzene sulphinate in dimethyl formamide solvent to yield l-((2E,6E,10E,14E,18E)- 3,7,l l,15,19,23-hexamethyl-l-(phenylsulfonyl)tetracosa-2,6,10,14,18,22-hexaen-9ylsulfonyl) benzene .

[0026] 1 ~ . 2E,6E, 1 OE, 14 , 18E)-3,7, 11 , 15, 19,23-hexamethyl

[0027] - 1 -(phenylsulfonyl)tetracosa-2,6, 10, 14, 18,22-hexaen-9-ylsulfonyl)benzene

[0028] M.W = 691.04

[0029] M.F = C42H5SO4S2

[0030] In an embodiment of the disclosure l-((2E,6E,10E,14E,18E)-3,7,l l,15,19,23-hexamethyl-l- (phenylsulfonyl)tetracosa-2,6,10,14,18,22-hexaen-9ylsulfonyl) benzene is reacted with 4- chloro prenyl acetate in the presence of Potassium t-Butoxide TBAB and 18-Crown-6 to obtain (2E,6E,10E,14E,18E,22E)-3,7,l l,15,19,23,27-heptamethyl-5,13-bis(phenylsulfonyl) octacosa - 2,6,10,14,18,22,26-heptaenyl acetate. In an embodiment of the disclosure (2E,6E,10E,14E,18E,22E)-3, 7, 11,15,19,23,27- heptamethyl-5,13-bis(phenylsulfonyl) octacosa - 2,6,10,14,18,22,26-heptaenyl acetate is hydrolysed in the presence of potassium hydroxide and methanol to (2E,6E,10E,14E,18E,22E)-3,7,l l,15,19,23,27-heptamethyl-5,13-bis(phenylsulfonyl) octacosa

[0031] - 2,6,10,14,18,22,26-heptaen-l-ol.

[0032] In an embodiment of the disclosure both phenyl sulphonyl groups in 2E,6E,10E,14E,18E,22E)- 3 ,7, 11, 15, 19, 23, 27-heptamethyl-5,13-bis(phenylsulfonyl)octacosa-2, 6, 10, 14,18,22,26- heptaen- l-ol are reduced in the presence of super hydride and tetrahydrofuran to yield (2E,6E,10E,14E,18E,22E)-3,7,ll,15,19,23,27-heptamethyloctacosa-2,6,10,14,18,22,26- heptaen-l-ol.

[0033] In an embodiment of the disclosure is disclosed a novel compound of the formula l-((2E,6E,10E,14E,18E)-3,7,l l,15,19,23-hexamethyl-l-(phenyl sulfonyl) tetracosa

[0034] -2,6,10,14,18,22-hexaen-9-ylsulfonyl)benzene

[0035] In an embodiment of the disclosure is disclosed a novel compound of the formula

[0036] (2E,6E,10E,14E,18E,22E)-3, 7, 11, 15, 19, 23, 27-heptamethyl -5,13-bis(phenyl sulfonyl )octacosa-2,6, 10, 14, 18,22,26-heptaen- 1 -ol DETAILED DESCRIPTION OF THE INVENTION

[0037] The invention is now described by examples which are representative and do not limit the scope of the invention.

[0038] Example 1

[0039] Preparation of 2,6,10,14,18,22-Tetracosahexaen-l-ol, 3,7,ll,15,19,23-hexamethyl-9- (phenylsulfonyl)-, (2E,6E,10E,14E,18E)- C30-SO2Ph-OH

[0040] 65.7 g (0.108 mol) C30-SO2Ph-OAc was dissolved in 197 ml methanol. The contents were cooled to 0 to 5°C. 1.812 g (0.032 mol) potassium hydroxide dissolved in 9.1 ml water was slowly added over 10 mins. Methanol was distilled off and the residue was extracted in ethyl 20 acetate. The reaction mass was quenched in water and acidified with 1 M HC1. Ethyl acetate layer was washed with water followed by brine and dried over anhydrous sodium sulphate. Ethyl acetate was distilled under vacuum to yield 61 g crude CSO-SChPh-OH as oil. It was purified by column chromatography to yield 40.1 g pure CSO-SChPh-OH as yellow oil. 'H NMR and13C NMR characterisation of CSO-SChPh-OH

[0041] 25 'H NMR (400 MHz, CDCh) 8 7.84 (D 2H), 7.62 (T 1H), 7.52 (T 2H), 5.38 (T 1H), 5.10 (M

[0042] 4H), 4.91 (D 1H), 4.12 (D 2H), 3.88 (T 1H), 2.89 (D 1H), 2.27 (T 1H), 1.93-2.04 (M 16H), 1.80 (Br 1H), 1.67 (S 3H), 1.62 (S 3H), 1.58 (S 9H), 1.52 (S 3H), 1.15 (S 3H). °C NMR (400 MHz, CDCE) 6 145.09, 139.05, 137.88, 135.60, 135.02, 133.38, 131.26, 130.17, 129.23, 128.69, 127.85, 124.35, 124.06, 123.56, 123.45, 117.20, 63.44, 59.24, 39.71, 39.19, 37.32, 30 26.73, 26.58, 26.57, 26.32, 25.72, 17.69, 16.34, 16.23, 16.02, 15.98, 15.93.

[0043] Example 2

[0044] Preparation of l-((2E,6E,10E,14E,18E)-l-chloro-3,7,ll,15,19,23-hexamethyl tetracosa- 2,6,10,14,18,22-hexaen-9-ylsulfonyl) benzene (C30-SC>2Ph-Cl).

[0045] 460 ml N, N-dimethyl formamide was cooled to -5°C. 36.33 g (0.265 mol) phosphorus trichloride was slowly added over 10-15 min at -5°C. The reaction mass was stirred for additional 30 mins maintaining the temperature constant. 200 g (0.353 mol) CSO-SChPh-OH dissolved in 240 ml N, N-dimethyl formamide was added to the above solution at 5-10°C over 20 mins. Reaction mass was stirred for additional 2 hrs at the same temperature and then quenched with sodium bicarbonate to adjust pH to 8 and extracted with Ethyl acetate. Organic layer was washed with water followed by brine and dried over anhydrous sodium sulphate. Ethyl acetate was distilled under vacuum to yield 215 g C3O-SO2PI1-CI as dark red coloured oil with 95% yield. Example 3

[0046] Preparation of l-((2E,6E,10E,14E,18E)-3,7,ll,15,19,23-hexamethyl -1- (phenyl sulfonyl) tetracosa-2,6,10,14,18,22-hexaen-9-ylsulfonyl) benzene : C30-(SC>2Ph)2

[0047] 79.6 g (0.485 mol) sodium benzene sulphinate in 473 ml N, N-dimethyl formamide was cooled to 10-15°C. 215 g (0.367 mol) C30-SO2Ph-Cl dissolved in 258 ml of N, N-dimethyl formamide, was added to the above solution over 10 mins at 10-15°C. Reaction mass was brought to room temperature and stirred for 15 hrs. It was then quenched with distilled water and extracted in Ethyl acetate. Organic layer was washed with water followed by brine and dried over anhydrous sodium sulphate. Ethyl acetate was distilled under vacuum to yield 232 g crude C30-(SO2Ph)2 as dark red colour oil with 84% yield. Crude product was purified by column chromatography in mixture of hexane and ethyl acetate to get pure product and characterized.

[0048] TH NMR and 13C NMR characterization of C30-(SO2Ph)2

[0049] 'H NMR (400 MHz, CDC13) 5 7.80 (M 4H), 7.62 (M 2H), 7.54 (M 4H), 5.10 (M 5H), 4.90 (D 1H), 3.90 (M 1H), 3.80 (D 1H), 2.89 (D 1H), 2.26 (T 1H), 1.95-2.05 (M 16H), 1.66 (S 3H), 1.58 (S 9H), 1.50 (S 3H), 1.28 (S 3H), 1.14 (S 3H).

[0050] °C NMR (400 MHz, CDCI3) 5 146.02, 145.13, 138.65, 137.88, 135.61, 133.59, 133.40, 131.22, 130.64, 129.22, 128.99, 128.71, 128.45, 127.29, 124.35, 124.05, 123.43, 117.20, 110.42, 63.41, 60.37, 55.99, 39.73, 39.28, 29.68, 26.73, 26.40, 25.88, 17.69, 16.35, 16.15, 16.02, 15.99 and 14.20.

[0051] Example 4

[0052] Preparation of (2E,6E,10E,14E,18E,22E)-3,7,ll,15,19,23,27-heptamethyl-5,13-bis(phenyl sulfonyl)octacosa-2,6,10,14,18,22,26-heptaenyl acetate (C35-(SC>2Ph)2-OAc).

[0053] 340 g (0.492 mol) C30-(SO2Ph)2 was dissolved in 952 ml tetrahydrofuran under inert atmosphere. 124 g (0.762 mol) 4-chloroprenyl acetate was added to it. The reaction mass was cooled to 0 to -5°C. 13.07 g. tetra butyl ammonium bromide and 2.13 g 18-Crown-6 were added. The reaction mass was stirred for 5 minutes maintaining the temperature constant. 82.65 g (0.736 mol) potassium tert-butoxide in 680 ml tetrahydrofuran were added to the above solution over 10 minutes and the reaction mass was stirred for 2 hrs maintaining the temperature constant and the reaction was continued overnight. The reaction mass was quenched into 20% ammonium chloride soln and pH was adjusted to 5-6 using 1 M HC1. Tetrahydrofuran was distilled off under vacuum and the residue was extracted in ethyl acetate. Ethyl acetate layer was washed with water followed by brine and dried over anhydrous sodium sulphate. Ethyl acetate was distilled under vacuum to yield 383 g crude C35-(SO2Ph)2-OAc as oil with 75% yield.

[0054] Example 5

[0055] Preparation of (2E,6E,10E,14E,18E,22E)-3,7,ll,15,19,23,27-heptamethyl-5,13-bis(phenyl sulfonyl)octacosa-2,6,10,14,18,22,26-heptaen-l-ol : C35-(SO2Ph)2-OH.

[0056] 18.9 g (0.028 mol) C35-(SO2Ph)2-OAc was dissolved in 57 ml methanol. The contents were cooled to 0 to 5°C. 0.47 g (0.0084 mol) potassium hydroxide dissolved in 2.35 ml water was slowly added over 5 mins, and the reaction mass was stirred overnight. Methanol was distilled off and the residue was extracted in ethyl acetate. The reaction mass was quenched into water and acidified with 1 M HC1. Ethyl acetate layer was washed with water followed by brine and dried over anhydrous sodium sulphate. Ethyl acetate was distilled off under vacuum to yield 17.6 g crude C35-(SO2Ph)2-OH as oil. Crude product was purified by column chromatography to yield 10.4 g pure C35-(SO2Ph)2-OH as yellow oil with 90% yield.

[0057] 'H NMR and 13C NMR characterization of C35-(SO2Ph)2-OH

[0058] 'H NMR (400 MHz, CDC13) 5 7.80 (T 4H), 7.57 (T 2H), 7.48 (T 4H), 5.35 (T 1H), 5.05 (M 4H), 4.85 (D 2H), 4.03 (M 3H), 3.88 (M 2H), 2.85 (D 2H), 2.24 (M 4H), 1.84-2.06 (M 18H), 1.63 (S 3H), 1.57 (S 12H), 1.48 (S 3H), 1.20 (S 3H).

[0059] °C NMR (400 MHz, CDCI3) 5 145.19, 137.76, 137.69, 135.56, 134.97, 133.51, 133.43, 133.29, 131.16, 129.15, 128.74, 128.70, 127.57, 127.55, 127.42, 127.35, 124.33, 124.04, 123.42, 117.17, 117.13, 117.09, 63.45, 63.41, 63.09, 60.36, 58.92, 39.71, 39.67, 39.65, 39.21, 37.25, 37.18, 26.70, 26.55, 26.38, 26.09, 25.69, 20.99, 17.67, 16.31, 16.23, 16.14, 15.99, 15.89, 15.83 and 14.16.

[0060] Example 6

[0061] Preparation of (2E,6E,10E,14E,18E,22E)-3,7,ll,15,19,23,27- heptamethyloctacosa-2,6,10, 14,18,22,26-heptaen-l-ol (C35-OH).

[0062] 100 g (0.129 mol) of C35-(SO2Ph)2-OH was dissolved in 1000 ml of Tetrahydrofuran under nitrogen atmosphere and 400 mg of (1,3-Bis (diphenyl phosphino) propane) palladium II chloride was added. The reaction mass was cooled to -5°C. 95.72 g (0.903 mol) super hydride solution was added in 60 minutes. Reaction mass was stirred at room temperature for 10-12 hrs. After completion of reaction, it was quenched by dropwise addition of methanol followed by acetic acid and stirred for 1 hr, THF was distilled off under vacuum and the residue was extracted twice with ethyl acetate. Ethyl acetate was washed off with water followed by brine and the residue was dried over anhydrous sodium sulphate. Ethyl acetate was distilled under vacuum to give 78 gm of crude C35-OH as oil with 84.47% yield

[0063] Crude product was purified by column chromatography in a mixture of hexane and ethyl acetate to recover pure product. Purity 90% 'H NMR and 13C NMR characterisation of Heptaprenol (C35-OH).

[0064] 'H NMR (400 MHz, CDC13) 5 5.45 (T 1H), 5.11 (M 6H), 4.17 (D 2H), 1.98-2.14 (M 24H), 1.70 (S 6H), 1.62 (S 18H), 1.30 (Br 1H).

[0065] °C NMR (400 MHz, CDCI3) 5 139.57, 135.32, 134.93, 134.85, 134.83, 131.15, 124.38, 124.23, 124.14, 123.74, 123.36, 59.28, 39.70, 39.54, 26.73, 26.64, 26.63, 26.30, 25.66, 17.64, 16.24, 15.98.

Claims

ClaimsWe Claim:

1. A process for the synthesis of (2E,6E,10E,14E,18E,22E)-3,7,ll,15,19,23,27-hepta methyl octacosa-2,6,10,14,18,22,26-heptaen-l-ol comprising a) reacting2E,6E, 10E, 14E, 18E)-3,7, 11, 15, 19, 23 -hexamethyl-9-(phenyl sulfonyl) tetracosa -2,6,10,14,18,22-hexaen-l-ol with PCh I dimethyl formamide and hexane to obtain 1 -((2E,6E, 1 OE, 14E, 18E)- 1 -chi oro-3 ,7,11,15,19,23 -hexamethyltetracosa-2, 6, 10, 14, 18,22- hexaen-9-ylsulfonyl)benzeneb) reacting 1- (2E,6E,10E,14E,18E)-l-chloro-3,7,ll,15,19,23-hexamethyltetracosa- 2,6,10,14,18,22- hexaen-9-ylsulfonyl)benzene with sodium benzene sulphinate in DMF to yield 1 -((2E,6E, 1 OE, 14E, 18E)-3 ,7, 11,15,19,23 -hexamethyl- 1 -(phenyl sulfonyl) tetracosa -2,6, 10, 14, 18,22-hexaen-9-ylsulfonyl)benzenec) reacting 1 -((2E,6E, 10E, 14E, 18E)-3,7, 11,15,19,23 -hexamethyl- 1 -(phenyl sulfonyl) tetracosa -2,6,10,14,18,22-hexaen-9-ylsulfonyl)benzene with 4- chloro prenyl acetate in the presence of Potassium t-Butoxide TBAB / and 18-Crown-6 in THF to yield (2E,6E, 10E, 14E, 18E,22E)-3 ,7, 11,15,19,23 ,27-heptamethyl -5,13 -bi s(phenyl sulfonyl) octacosa -2,6,10,14,18,22,26-heptaenyl acetated) hydrolysing(2E,6E, 10E, 14E, 18E,22E)-3,7, 11,15,19,23,27-heptamethyl-5, 13- bis(phenyl sulfony octacosa -2,6,10,14,18,22,26-heptaenyl acetate tin the presence of KOH and methanol to (2E,6E,10E,14E,18E,22E)-3,7,ll,15,19,23,27-heptamethyl -5,13 -bi s(phenyl sulfonyl)octacosa-2, 6, 10,14,18,22,26-heptaen- 1 -ole) reducing (2E,6E,10E,14E,18E,22E)-3,7,l l,15,19,23,27-heptamethyl -5,13 -bis (phenylsulfonyl)octacosa-2,6,10,14,18,22,26-heptaen-l-ol in the presence of super hydride in THF to (2E,6E,10E,14E,18E,22E)-3,7,ll,15,19,23,27- heptamethyl octacosa-2, 6, 10,14,18,22,26-heptaen- 1 -ol .

2. A compound of the formula1 -((2E,6E, 1 OE, 14E, 18E)-3 ,7, 11,15,19,23 -hexamethyl- 1 -(phenyl sulfonyl) tetracosa -2,6,10,14,18,22-hexaen-9-yl sulfonyl) benzene3. A compound of the formula(2E,6E, 1 OE, 14E, 18E,22E)-3 ,7,11,15,19,23 ,27-heptamethyl -5,13 -bi s(phenyl sulfonyl) octacosa-2,6,10,14,18,22,26-heptaen-l-ol.

Citation Information

Patent Citations

  • Polyprenyl alcohol-containing injections and use thereof

    EP0239729B1

  • Process for the preparation of vitamin K2

    US9012693B2

  • Method of preparation of stereospecific quinone derivatives

    US9464021B2

  • Crystalline menoquinone-7 (vitamin k2)

    WO2010034999A1

  • Process for the preparation of vitamin k2

    WO2011117324A2